Predictions
Lumentum Holdings Inc
Start price
Target price
Perf. (%)
€40.19
10.10.16
10.10.16
€45.10
31.10.16
31.10.16
-15.00%
31.10.16
31.10.16
Clovis Oncology Inc.
Start price
Target price
Perf. (%)
€25.41
08.10.16
08.10.16
€32.93
17.11.16
17.11.16
29.89%
17.11.16
17.11.16
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€78.24
06.10.16
06.10.16
€85.69
02.10.17
02.10.17
75.28%
02.10.17
02.10.17
Booking Holdings Inc.
Start price
Target price
Perf. (%)
€1,346.4
06.10.16
06.10.16
€1,357.5
5.18%
08.11.16
08.11.16
Market Leader or Top 3
Well known brand
Very small cyclical dependencies
High challenges to pay loans and raise capital
Paypal Holdings Inc
Start price
Target price
Perf. (%)
€36.54
05.10.16
05.10.16
€45.10
16.05.17
16.05.17
23.48%
16.05.17
16.05.17
Booking Holdings Inc.
Start price
Target price
Perf. (%)
€1,347.8
04.10.16
04.10.16
€1,353.0
0.42%
05.10.16
05.10.16
Market Leader or Top 3
Well known brand
Very small cyclical dependencies
High challenges to pay loans and raise capital
Larimar Therapeutics Inc.
Start price
Target price
Perf. (%)
€37.88
04.10.16
04.10.16
€44.38
31.01.17
31.01.17
17.14%
31.01.17
31.01.17
Abbott Laboratories
Start price
Target price
Perf. (%)
€38.42
04.10.16
04.10.16
€44.20
05.12.16
05.12.16
-10.41%
05.12.16
05.12.16
Imprimis Pharmaceuticals Inc
Start price
Target price
Perf. (%)
?3.41
03.10.16
03.10.16
€3.88
18.10.16
18.10.16
-19.01%
18.10.16
18.10.16
Imprimis Pharmaceuticals Inc
Start price
Target price
Perf. (%)
?3.41
02.10.16
02.10.16
€3.88
29.03.17
29.03.17
14.86%
29.03.17
29.03.17
Advanced Cannabis Solutions Inc.
Start price
Target price
Perf. (%)
€2.27
01.10.16
01.10.16
€3.00
11.10.16
11.10.16
35.06%
11.10.16
11.10.16
Endo International
Start price
Target price
Perf. (%)
€18.51
30.09.16
30.09.16
€22.55
03.11.16
03.11.16
-13.11%
03.11.16
03.11.16
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€70.48
30.09.16
30.09.16
€98.00
08.09.26
08.09.26
22.27%
18:08
18:08
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued